10-K: Quanterix: Akoya Integration, Alzheimer's Test Advance

Quanterix reports increased revenue driven by strategic acquisitions and progress in Alzheimer's diagnostics, despite a significant rise in net loss and macroeconomic headwinds.

Summary

• Total revenues increased by 1% to $138.9 million for the fiscal year ended December 31, 2025, up from $137.4 million in 2024.
• Net loss significantly widened to $107.2 million in 2025, compared to $38.5 million in 2024.
• Acquired Akoya Biosciences, Inc. on July 8, 2025, for $151.0 million, expanding into spatial biology and diversifying revenue into oncology and immunology.
• Acquired Emission, Inc. on January 8, 2025, for $9.0 million upfront, plus potential earnouts, to secure proprietary magnetic beads for next-generation platforms.
• Submitted a 510(k) premarket notification to the FDA on January 31, 2026, for a multi-analyte algorithmic blood test for Alzheimer's disease, which previously received Breakthrough Device Designation.
• The Centers for Medicare & Medicaid Services (CMS) approved a reimbursement rate of $897 for the LucentAD Complete multiplex test in November 2025.
• Implemented cost reduction actions in 2025, achieving approximately $74.0 million in annualized synergies, with a goal to reach $85.0 million in total annualized operating expense reductions in 2026.
• Incurred a $6.4 million goodwill impairment charge in the second quarter of 2025, primarily due to a larger-than-expected decline in revenue and bookings from macroeconomic conditions.
• Experienced significant board and management transitions in late 2025 and early 2026, including the appointment of Everett Cunningham as CEO.
• The company expects to be cash flow breakeven in 2026, contingent on meeting revenue and expense objectives.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with mixed sentiment. While strategic acquisitions and significant progress in Alzheimer's diagnostics are positive, the substantial increase in net loss and goodwill impairment due to macroeconomic headwinds present considerable financial challenges.

Positives

• Total revenues increased by 1% to $138.9 million in 2025, primarily driven by strategic acquisitions.
• The acquisition of Akoya Biosciences, Inc. on July 8, 2025, expanded the company's technology offerings into spatial biology, oncology, and immunology, diversifying revenue from over 90% neurology to approximately 60% neurology and 40% oncology.
• The acquisition of Emission, Inc. on January 8, 2025, secured proprietary magnetic beads for next-generation platforms and expanded into a new multi-plex segment.
• Submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test for Alzheimer's disease, which previously received Breakthrough Device Designation.
• CMS approved a reimbursement rate of $897 for the LucentAD Complete multiplex test in November 2025, providing a nationally recognized reference price and enabling broader access.
• Achieved approximately $74.0 million in annualized operating expense synergies in 2025 from cost reduction actions, with a target of $85.0 million in total annualized reductions for 2026.
• Remediated previously identified material weaknesses in internal control over financial reporting as of December 31, 2025.
• Expanded its network of partners providing Simoa technology for Alzheimer's testing, adding 13 new partnerships in 2025 for a total of 25 partners.

Negatives

• Net loss significantly increased to $107.2 million in 2025, compared to $38.5 million in 2024.
• Incurred a $6.4 million goodwill impairment charge in the second quarter of 2025 due to a larger-than-expected decline in revenue and bookings.
• Legacy Quanterix business product revenue decreased by $8.7 million, or 11%, primarily due to decreased demand for consumables from changing macroeconomic conditions.
• Service and other revenue for the legacy Quanterix business decreased by $18.8 million, or 37%, due to macroeconomic conditions impacting demand for large projects and the completion of an agreement with Eli Lilly and Company.
• Collaboration and license revenue decreased by $3.0 million, or 66%, due to non-recurring LDT and diagnostic-related license revenues in 2024.
• Grant revenue decreased by $1.7 million, or 88%, due to the completion of milestones under certain grants in 2024.
• Operating expenses increased by 40% to $190.5 million in 2025, from $135.7 million in 2024, partly due to acquisition and integration costs and impairment charges.

Risks

• Quarterly and annual operating results and cash flows have fluctuated and might continue to fluctuate, potentially causing common stock value to decline.
• The company has incurred annual losses since formation and expects to incur losses in the future, with no certainty of achieving or sustaining profitability.
• Inherent limitations in internal control over financial reporting could result in material misstatements in financial statements.
• Integrating the acquired Akoya business may be more difficult, costly, or time-consuming than expected, potentially failing to realize anticipated benefits.
• Failure to achieve expected cost savings from reduction actions or adverse impacts from these actions could harm the business.
• Recent turnover in the board of directors and management could lead to changes in strategic plans, product focus, and investment priorities, potentially delaying benefits.
• Failure of products to achieve and sustain sufficient market acceptance would adversely affect revenue.
• Sales of Simoa-based assays for neurological indications are increasingly important, and there is no assurance of continued meaningful revenue from these products.
• Penetrating the diagnostics market entails significant risks, including substantial investments, complex regulatory frameworks, competition, and reimbursement challenges.
• The sales cycle for instruments can be lengthy and variable, making revenue forecasting difficult.
• Customer purchases of instruments require significant capital investment, impacting sales during constrained spending periods.
• A significant portion of revenue comes from a few large customers, making the company vulnerable to decreases in sales to these customers.
• Long-term results depend on the ability to improve existing products and successfully introduce and market new products in a rapidly changing technological environment.
• Delays in launching and commercializing next-generation instruments could adversely affect the business.
• Defects or quality issues in products could lead to unforeseen costs, recalls, regulatory actions, negative publicity, and litigation.
• Generating a substantial portion of revenue internationally exposes the business to various risks related to international activities.
• Reliance on distributors for international sales could impact revenue.
• Reliance on single contract manufacturers for key instruments and a limited number of suppliers for materials and components poses supply chain risks.
• Significant competition in the life sciences research and diagnostic markets could hinder revenue growth and profitability.
• Changes in U.S. government policies, including reductions in federal research funding and impacts of tariffs, are adversely affecting the business.
• Potential FDA regulation of products as medical devices or new laws subjecting LDTs to FDA regulation would be expensive, time-consuming, and uncertain.
• Future product recalls could harm reputation, business, and financial results.
• U.S. legislative, FDA, or global regulatory reforms may make it more difficult and costly to obtain regulatory approval and market products.
• Non-compliance with governmental regulations applicable to CLIA-certified laboratories could halt laboratory operations or LDT offerings.
• Reliance on third parties for future diagnostic product studies may lead to unsatisfactory performance.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies for diagnostic procedures could harm the business.
• Dependence on information technology systems means any failure could harm the business.
• Cybersecurity breaches, data loss, and other disruptions could compromise sensitive information and expose the company to liability.
• Inability to adapt to and effectively incorporate potential advantages of artificial intelligence (AI) could negatively impact competitiveness, and inability to manage AI risks could expose the company to liability.
• Inability to protect intellectual property could reduce technological or competitive advantage.

Future Outlook

The company expects to incur operating losses into 2026 as it executes its growth strategy, but anticipates being cash flow breakeven in 2026, dependent on meeting revenue and expense objectives. It plans to continue investing in research and development, expanding into diagnostics, and building the global infrastructure for Alzheimer's disease testing.

Management Comments

• The selection process for new board members and the CEO reflects a deliberate enhancement of technology, commercial, spatial, and diagnostics expertise across leadership.
• The multi-analyte test submission to the FDA represents a significant milestone in the company's mission to provide superior, non-invasive, high-performance diagnostic tools for Alzheimer's disease.
• The CMS reimbursement rate for LucentAD Complete is an important step for coverage decisions with payers, enabling broader access and supporting efforts to bring this diagnostic solution to hospitals and laboratories.

Industry Context

StockSavvy.ai notes Quanterix's strategic positioning in ultra-sensitive biomarker detection and spatial biology aligns with the growing demand for early disease detection and personalized medicine, particularly in neurology and oncology. The FDA's recent actions on blood tests for Alzheimer's disease and CMS reimbursement for LucentAD Complete are favorable industry trends that could accelerate adoption of less-invasive diagnostic tools. However, the broader macroeconomic headwinds, including reductions in federal research funding and pharmaceutical R&D spending, reflect a challenging environment for capital equipment sales and large research projects across the life sciences sector.

Comparison to Industry Standards

• StockSavvy.ai observes Quanterix's ultra-sensitive Simoa technology and spatial biology platforms offer differentiation against competitors like Bio-Techne, MesoScale Discovery, SEER, Bio-Rad Laboratories, Alamar, Spear Bio, 10x Genomics, Vizgen, Bruker, Miltenyi Biotec, and Standard BioTools by enabling detection of low-abundance proteins in blood and multiplexed tissue analysis at single-cell resolution, crucial for early disease detection and understanding complex biological systems.
• The LucentAD Complete test's reported 'best-in-class performance for amyloid detection accuracy' and reduced uncertainty in borderline cases positions it favorably against existing diagnostic approaches for Alzheimer's, such as PET imaging and CSF biomarkers, which are invasive and expensive.
• The company's expansion into diagnostics, particularly with FDA Breakthrough Device Designation and CMS reimbursement for LucentAD Complete, indicates a move towards clinical applications that could challenge traditional diagnostic methods and compete with established IVD companies like Roche, Fujirebio, Danaher, and C2N Diagnostics.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any pending or threatened litigation, the outcome of which would be expected to have a material adverse effect on its financial condition or results of operations.

Related Party Transactions

• A diagnostic development agreement with a biopharmaceutical customer of Akoya's involves a member of the company's board of directors also serving on the board of the biopharmaceutical customer. Revenue from this customer was $4.8 million in 2025.
• Agreements were entered into with two entities owned by selling shareholders of Emission for continued development work on future products for Quanterix. A portion of the Earnout 1 payment for the Emission acquisition was paid to these entities in 2025.
• The Harvard License Agreement for intellectual property involves a former board member affiliated with Harvard and Mass General Brigham, who receives a portion of payments from the company to Harvard. Revenue from Harvard and its affiliates, and Mass General Brigham and its affiliates, totaled $1.5 million in 2025.
• The Tufts License Agreement for intellectual property involves a former board member affiliated with Tufts, who received compensation from Tufts based on royalties and license payments made by the company. Royalty expenses related to this agreement were $1.5 million in 2025.

Stakeholder Impact

• Shareholders: Experience dilution from equity offerings for acquisitions and potential future capital raises. Face increased net losses and goodwill impairment, but also potential long-term growth from strategic acquisitions and diagnostic market penetration.
• Employees: Subject to workforce reductions as part of cost-saving and integration efforts, but also benefit from competitive compensation, benefits, and a focus on inclusive culture and wellness.
• Customers: Benefit from expanded product offerings in spatial biology and ultra-sensitive diagnostics, particularly in neurology, oncology, and immunology. May face impacts from macroeconomic conditions affecting research funding and R&D spending.
• Suppliers/Contract Manufacturers: Continued reliance on single-source suppliers and contract manufacturers creates dependency, but also provides ongoing business for these partners.
• Regulatory Authorities: Engaged with FDA for 510(k) submission and Breakthrough Device Designation, and CMS for reimbursement, indicating compliance and collaboration in bringing new diagnostics to market.

Next Steps

• Grow menu through rapid internal assay expansion, expecting increased consumable pull-through.
• Continue to grow leadership position in neuro-based biomarkers, leveraging their importance for therapeutics and diagnostics.
• Expand further into indications beyond neurology, particularly oncology and immunology, through internal R&D and combining tissue and blood biomarker detection capabilities.
• Expand presence in the diagnostics market with less-invasive tests, potentially replacing current invasive methods.
• Help build the global infrastructure for Alzheimer's disease testing and diagnosis by enabling partners and offering LucentAD Complete.
• Launch an early access program for the next-generation instrument 'Simoa ONE' in late 2025 to gather feedback.
• Take additional steps in 2026 to further reduce operating expenses, targeting a total annualized reduction of $85.0 million.

Key Dates

Recommendation

The company presents a mixed financial picture with significant strategic advancements offset by substantial financial losses and macroeconomic challenges. While the acquisitions of Akoya and Emission, along with progress in Alzheimer's diagnostics (FDA submission, Medicare reimbursement), position Quanterix for future growth and market diversification, the sharp increase in net loss and goodwill impairment in 2025 indicate operational and integration hurdles. The outlook for cash flow breakeven in 2026 is positive but contingent. A 'hold' recommendation reflects the balance between these promising strategic developments and the current financial underperformance and execution risks.

Keywords

Biomarkers, Alzheimer's Disease, Spatial Biology, Simoa Technology, Diagnostics, Life Sciences, Oncology, Immunology, Neurodegenerative Conditions, Ultra-sensitive Detection, Medical Devices, SEC Filing, 10-K